Abstract:Cisplatin‐induced kidney injury (CKI) is a common complication of chemotherapy. Fraxetin, derived from Fraxinus bungeana A. DC. bark, has antioxidant, anti‐inflammatory, and anti‐fibrotic effects. This study aims to investigate fraxetin's effects on CKI and its underlying mechanism in vivo and in vitro. Tubular epithelial cells (TECs) and mice were exposed to cisplatin with and without fraxetin preconditioning assess fraxetin's role in CKI. TECs autophagy was observed using transmission electron microscopy. Apoptosis levels in animal tissues were measured using TUNEL staining. The protective mechanism of fraxetin was explored through pharmacological and genetic regulation of mTORC1. Molecular docking was used to identify potential binding sites between fraxetin and mTORC1. Fraxetin pretreatment reduced cisplatin‐induced kidney injury in a time‐ and concentration‐dependent way. Fraxetin also decreased autophagy in TECs, as observed through electron microscopy. Tissue staining confirmed that fraxetin pretreatment significantly reduced cisplatin‐induced apoptosis. Inhibition of mTORC1 using rapamycin or siRNA reversed the protective effects of fraxetin on apoptosis and autophagy in cisplatin‐treated TECs, while activation of mTORC1 enhanced fraxetin's protective effect. Molecular docking analysis revealed that fraxetin can bind to HEAT‐repeats binding site on mTORC1 protein. These findings indicated that fraxetin pretreatment alleviates CKI by antagonizing autophagy and apoptosis via mTORC1 activation. This provides evidence for the potential therapeutic application of fraxetin in CKI. Cisplatin‐induced kidney injury (CKI) is a common complication of chemotherapy. Fraxetin, derived from Fraxinus bungeana A. DC. bark, has antioxidant, anti‐inflammatory, and anti‐fibrotic effects. This study aims to investigate fraxetin's effects on CKI and its underlying mechanism in vivo and in vitro. Tubular epithelial cells (TECs) and mice were exposed to cisplatin with and without fraxetin preconditioning assess fraxetin's role in CKI. TECs autophagy was observed using transmission electron microscopy. Apoptosis levels in animal tissues were measured using TUNEL staining. The protective mechanism of fraxetin was explored through pharmacological and genetic regulation of mTORC1. Molecular docking was used to identify potential binding sites between fraxetin and mTORC1. The results indicated that fraxetin pretreatment reduced cisplatin‐induced kidney injury in a time‐ and concentration‐dependent way. Fraxetin also decreased autophagy in TECs, as observed through electron microscopy. Tissue staining confirmed that fraxetin pretreatment significantly reduced cisplatin‐induced apoptosis. Inhibition of mTORC1 using rapamycin or siRNA reversed the protective effects of fraxetin on apoptosis and autophagy in cisplatin‐treated TECs, while activation of mTORC1 enhanced fraxetin's protective effect. Molecular docking analysis revealed that fraxetin can bind to HEAT‐repeats binding site on mTORC1 protein. In summary, fraxetin pretreatment alleviates CKI by antagonizing autophagy and apoptosis via mTORC1 activation. This provides evidence for the potential therapeutic application of fraxetin in CKI.

Fraxin Prevents Chemically Induced Hepatotoxicity by Reducing Oxidative Stress

Hepatoprotective Effect of Fraxin Against Carbon Tetrachloride-Induced Hepatotoxicity in Vitro and in Vivo Through Regulating Hepatic Antioxidant, Inflammation Response and the MAPK-NF-κB Signaling Pathway

Protective Effects of the Flavonoid-Rich Fraction from Rhizomes of Smilax Glabra Roxb. on Carbon Tetrachloride-Induced Hepatotoxicity in Rats.

Protective effects of fraxin on cerebral ischemia-reperfusion injury by mediating neuroinflammation and oxidative stress through PPAR-γ/NF-κB pathway

Fraxin Ameliorates Lipopolysaccharide-Induced Acute Lung Injury in Mice by Inhibiting the NF-κB and NLRP3 Signalling Pathways.

Fraxin (7-hydroxy-6-methoxycoumarin 8-glucoside) confers protection against ionizing radiation-induced intestinal epithelial injury in vitro and in vivo

[Improving the Solubility of Fraxinellone to Increase Its Oral Bioavailability and Hepatoprotective Action Against Acute Liver Injury in Mice].

Fraxinellone Induces Hepatotoxicity in Zebrafish through Oxidative Stress and the Transporters Pathway

Fraxin inhibits lipopolysaccharide-induced inflammatory cytokines and protects against endotoxic shock in mice.

Fraxin Inhibits Melanogenesis by Suppressing the ERK/MAPK Pathway and Antagonizes Oxidative Stress by Activating the NRF2 Pathway

Fraxetin Ameliorates Symptoms of Dextran Sulphate Sodium-Induced Colitis in Mice

Fraxetin Induces Heme Oxygenase-1 Expression by Activation of Akt/Nrf2 or AMP-activated Protein Kinase α/Nrf2 Pathway in HaCaT Cells

Fraxetin prevented sodium fluoride-induced chronic pancreatitis in rats: Role of anti-inflammatory, antioxidant, antifibrotic and anti-apoptotic activities

Fraxin Represses NF-κB Pathway Via Inhibiting the Activation of Epidermal Growth Factor Receptor to Ameliorate Diabetic Renal Tubulointerstitial Fibrosis.

7-Hydroxy-6-methoxycoumarin 8-Glucoside (fraxin) Confers Protection Against Ionizing Radiation-Induced Intestinal Epithelial Cell Death Both in Vitro and in Vivo.

Fraxin Promotes the Activation of Nrf2/ARE Pathway via Increasing the Expression of Connexin43 to Ameliorate Diabetic Renal Fibrosis

Tectorigenin Protects Against Experimental Fulminant Hepatic Failure by Regulating the TLR4/mitogen‐activated Protein Kinase and TLR4/nuclear Factor‐κb Pathways and Autophagy

Fraxetin alleviates microglia-mediated neuroinflammation after ischemic stroke

Fraxetin pretreatment alleviates cisplatin‐induced kidney injury by antagonizing autophagy and apoptosis via mTORC1 activation

In Vitro and In Vivo Antifibrotic Effects of Fraxetin on Renal Interstitial Fibrosis via the ERK Signaling Pathway

Fraxetin Inhibits Interleukin-1Β-induced Apoptosis, Inflammation, and Matrix Degradation in Chondrocytes and Protects Rat Cartilage in Vivo.